NCT00777348已完成2 期
Clinical Trial to Assess the Protective Effect of the Fixed Drug Combination of Disodium Cromoglycate Plus Reproterol in Comparison to the Single Components and Placebo in Adults With Exercise Induced Asthma Randomised, Placebo-controlled, Double-blind, Crossover, Multicentre Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 62
- 试验地点
- 7
- 主要终点
- Primary objective: to demonstrate superiority of the protective effect of the fixed combination of disodium cromoglycate (DSCG) plus reproterol in comparison to the single component reproterol in adults suffering from exercise induced asthma (EIA).
研究概览
简要总结
This is a multicentre, randomised, double-blind, placebo-controlled, 4-way cross-over study. At each study visit a standardised treadmill test will be performed to provoke EIA. Before and after the challenge test pulmonary function variables (e.g. forced expiratory volume in one second (FEV1)) will be measured in order to assess the protective effect of the study medication.
详细描述
- Primary objective: to demonstrate superiority of the protective effect of the fixed combination of disodium cromoglycate (DSCG) plus reproterol in comparison to the single component reproterol in adults suffering from exercise induced asthma (EIA).
- Secondary objectives: to demonstrate superiority of the protective effect of DSCG plus reproterol in comparison to the single component DSCG; to demonstrate superiority of the protective effect of each single component in comparison to placebo. In addition, the tolerability of medications will be documented.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Female and male subjects aged 18 - 65 years
- •Exercise induced asthma with reversible airway obstruction: twice proven EIA defined as maximum decrease in FEV1 against the baseline value of at least 20% (first test results can be obtained during the last 12 months)
- •Baseline FEV1 before challenge must be > or = 70% of the predicted FEV1
排除标准
- •Safety concerns:
- •Subjects with hypersensitivity to DSCG, reproterol, menthol, peppermint or other excipients of the study medication
- •Pregnancy, breast-feeding or planned pregnancy during the study. Women of child bearing potential not using a highly effective method of birth control defined as those which result in a low failure rate (i.e. <1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, hormonal IUDs, tubal ligation or vasectomised partner
- •Subjects with an asthma exacerbation within 4 weeks prior to the study start. Asthma exacerbation defined as use of oral (systemic) glucocorticosteroids, unscheduled consultation of a medic due to asthma, hospitalisation, or additional treatment of asthma with antibiotics
- •Eosinophilic pneumonia
- •Clinically significant cardiovascular diseases (e.g. cardiac infarction, cardiac dysrhythmia, hypertrophic obstructive cardiomyopathy, coronary heart disease...)
- •Resting blood pressure over 140/90 mmHg
- •Diastolic blood pressure after treadmill-test over 120 mmHg
- •Malignancies including phaeochromocytoma within the last 5 years
- •Severe hyperthyreosis, thyreotoxicosis, instable diabetes mellitus
- •Lack of suitability for the trial:
- •Subjects with seasonal asthma during their asthma season
- •Infectious disease of the upper airways within 2 weeks prior to the study and within 4 weeks prior to study in case of use of antibiotics
- •Relevant respiratory disorder other than asthma
- •Clinically significant renal, endocrine, haematological, hepatic, immunological, gastrointestinal, neurological, or psychiatric diseases
- •Any chronic disease which might influence absorption, metabolism, or excretion of the trial substances
- •Change of inhalative glucocorticosteroid dosage and / or antiasthmatic controller therapy within the last 4 weeks prior to or during the study
- •Concomitant systemic treatment with glucocorticosteroids
- •Concomitant treatment with any ß-antagonistic drug
- •Need of rescue medication within 15 min after challenge
- •Concomitant therapy with antidepressants or neuroleptics
- •Drug or alcohol abuse which would interfere with the subjects proper completion of the protocol assignment and mentally handicapped subjects
- •Smokers within the last 6 months or smoking history > 10 pack-years (a pack-year is 20 cigarettes per day for one year or equivalent)
- •Exposure to another investigational agent within the last 4 weeks prior to this one or during this study
- •Non-cooperative subjects not able to understand the instructions for use of the devices
- •Administrative reasons:
- •Lack of ability or willingness to give informed consent
- •Lack of willingness to have personal study related data collected, archived or transmitted according to protocol
- •Anticipated non-availability for study visits / procedures
- •Personnel involved in the planning or conduct of the study
研究组 & 干预措施
1
Experimental
DSCG + Reproterol
干预措施: Combination DSCG and Reproterol (Drug)
2
Active Comparator
DSCG
干预措施: Combination DSCG and Reproterol (Drug)
3
Active Comparator
Reproterol
干预措施: Combination DSCG and Reproterol (Drug)
4
Placebo Comparator
Placebo
干预措施: Combination DSCG and Reproterol (Drug)
结局指标
主要结局
Primary objective: to demonstrate superiority of the protective effect of the fixed combination of disodium cromoglycate (DSCG) plus reproterol in comparison to the single component reproterol in adults suffering from exercise induced asthma (EIA).
时间窗: 5, 10, 15, 30 and 60 minutes after drug application
次要结局
- Secondary objectives: to demonstrate superiority of the protective effect of DSCG plus reproterol in comparison to the single component DSCG; to demonstrate superiority of the protective effect of each single component in comparison to placebo.(5, 10, 15, 30 and 60 minutes after drug application)
研究者
研究点 (7)
Loading locations...
相似试验
已完成
2 期
Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic DermatitisAtopic DermatitisPruritusNCT04018027Cara Therapeutics, Inc.401
已完成
4 期
Long Term Influenza Prophylaxis With Inhaled Zanamivir or Oral OseltamivirInfluenzaNCT00980109University of Oxford390
已完成
3 期
Efficacy and Safety Study of Nicotine Mint Lozenge (2mg and 4mg) in Smoking CessationSmokingNCT00985985GlaxoSmithKline723
尚未招募
4 期
A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate in Vascular Cognitive Impairment PatientsVascular Cognitive ImpairmentNCT05050604Chong Kun Dang Pharmaceutical418
已完成
4 期
A Clinical Trial to Evaluate the Efficacy and Safety of YMC026 in Respiratory Disease PatientsRespiratory DiseaseNCT03334916Yuhan Corporation223